Last updated: September 1, 2026
Cabazitaxel, marketed by Sanofi as Jevtana, is an intravenous taxane approved for metastatic castration-resistant prostate cancer after docetaxel treatment. Its commercial profile has shifted from branded growth to mature-market erosion. Sanofi sales have declined from the product’s peak as generic cabazitaxel injections entered the United States and other markets. The remaining value lies in oncology demand, treatment-line persistence, manufacturing complexity, and geographic markets where generic penetration remains limited.
What is cabazitaxel and how is it used?
Cabazitaxel is a semisynthetic taxane that inhibits microtubule depolymerization. Jevtana is administered with prednisone or prednisolone for adults with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.
The principal FDA-approved regimen is 20 mg/m² intravenously every three weeks with daily prednisone. A 25 mg/m² dose may be used in selected patients, although the higher dose carries greater risks of neutropenia, diarrhea, renal complications, and other toxicities. The FDA label recommends primary prophylaxis with granulocyte colony-stimulating factor for patients with elevated risk of febrile neutropenia (U.S. Food and Drug Administration [FDA], 2023).
Cabazitaxel product profile
| Attribute |
Jevtana and cabazitaxel |
| Active ingredient |
Cabazitaxel |
| Drug class |
Taxane antineoplastic |
| Route |
Intravenous infusion |
| Initial FDA approval |
June 17, 2010 |
| Original indication |
Metastatic hormone-refractory prostate cancer after docetaxel |
| Current principal indication |
Metastatic castration-resistant prostate cancer after docetaxel |
| Combination partner |
Prednisone or prednisolone |
| Sponsor |
Sanofi |
| FDA application |
NDA 201023 |
| Key commercial constraint |
Hospital and oncology-provider purchasing, infusion administration, generic injectable competition |
Jevtana is a late-line prostate cancer treatment. Its use is constrained by prior docetaxel exposure, treatment tolerability, patient performance status, and the availability of androgen-receptor pathway inhibitors, radioligand therapies, PARP inhibitors, and other agents.
What is the market size and competitive position for cabazitaxel?
Cabazitaxel competes in a mature segment of metastatic castration-resistant prostate cancer rather than in the broader prostate cancer market. Most prostate cancer patients do not receive cabazitaxel. The target population consists primarily of patients whose disease progresses despite androgen-deprivation therapy and prior docetaxel treatment.
Principal competing therapies
| Therapy |
Drug class |
Typical competitive role |
| Cabazitaxel |
Taxane chemotherapy |
Post-docetaxel metastatic castration-resistant disease |
| Docetaxel |
Taxane chemotherapy |
Earlier chemotherapy line; also prior exposure requirement for cabazitaxel |
| Abiraterone |
CYP17 inhibitor |
Hormone-sensitive and castration-resistant disease |
| Enzalutamide |
Androgen-receptor inhibitor |
Hormone-sensitive and castration-resistant disease |
| Apalutamide |
Androgen-receptor inhibitor |
Primarily earlier-line hormone-sensitive disease |
| Darolutamide |
Androgen-receptor inhibitor |
Nonmetastatic and metastatic hormone-sensitive settings |
| Lutetium-177 vipivotide tetraxetan |
Radioligand therapy |
PSMA-positive metastatic castration-resistant disease |
| Olaparib and other PARP inhibitors |
DNA-repair targeted therapy |
Biomarker-selected disease |
| Radium-223 |
Alpha-particle radiopharmaceutical |
Symptomatic bone-predominant disease without visceral metastases |
Cabazitaxel retains clinical relevance when disease progresses after docetaxel and an androgen-receptor pathway inhibitor. The CARD trial showed improved radiographic progression-free survival and overall survival for cabazitaxel compared with the alternative androgen-signaling inhibitor in men previously treated with docetaxel and abiraterone or enzalutamide (de Wit et al., 2019). That evidence supports continued use in a defined treatment sequence, but the addressable population is narrower than the populations for leading oral prostate cancer therapies.
What drives cabazitaxel demand?
Demand is influenced by five factors:
- The number of patients reaching metastatic castration-resistant disease after docetaxel.
- Treatment sequencing after abiraterone or enzalutamide.
- Physician willingness to use intravenous chemotherapy in late-line disease.
- Hospital and oncology-clinic reimbursement.
- Generic price competition and procurement substitution.
Cabazitaxel demand is less sensitive to new-patient diagnosis volumes than oral prostate cancer drugs. It is more dependent on treatment duration, line-of-therapy guidelines, and the clinical fitness of heavily pretreated patients.
What is the financial trajectory of Jevtana?
Jevtana has moved into a declining mature-product phase. Sanofi’s public reporting shows a multiyear reduction from earlier peak sales as the United States and other markets absorbed generic competition and the product faced substitution by newer oncology therapies.
Reported Sanofi sales trend
Sanofi reports Jevtana revenue within its specialty-care and oncology reporting. Public annual reports indicate the following approximate trajectory:
| Fiscal year |
Jevtana sales trend |
| 2019 |
Approximately €370 million |
| 2020 |
Approximately €350 million |
| 2021 |
Approximately €315 million |
| 2022 |
Approximately €280 million to €300 million |
| 2023 |
Approximately €250 million to €270 million |
| 2024 |
Continued decline from 2023 levels |
The reported decline reflects generic entry, lower branded utilization in the United States, and the maturity of cabazitaxel’s treatment market. Exact year-to-year figures can differ depending on Sanofi’s reporting currency, geographic presentation, and restatement conventions (Sanofi, 2020, 2021, 2022, 2023, 2024).
Financial exposure by market
The United States historically represented the most important commercial market because of its oncology reimbursement infrastructure and higher branded pricing. That exposure also created the greatest downside after FDA-approved injectable generics entered the market.
European markets generally have stronger price controls and centralized procurement. Generic erosion can therefore reduce price and volume simultaneously, although market-entry timing differs by country. Emerging markets may support residual unit growth, but lower prices and tender-based purchasing constrain revenue conversion.
Jevtana’s commercial value is now more consistent with a specialty mature product than a growth asset. Its economics depend on maintaining manufacturing reliability, retaining institutional contracts, and limiting the pace of branded-to-generic substitution.
When did cabazitaxel lose exclusivity?
Cabazitaxel’s original composition-of-matter protection expired before the current market. The key U.S. patent commonly associated with cabazitaxel is U.S. Patent No. 5,847,170, covering taxoid derivatives and related compounds. Its effective patent term ended in the mid-2010s, subject to patent-term adjustment or extension analysis.
The product’s commercial protection therefore depended on more than the basic active-ingredient patent. Regulatory exclusivity, formulation claims, use claims, patent litigation, and settlement terms affected the timing of generic entry.
Cabazitaxel exclusivity timeline
| Date |
Event |
| 1994 |
Priority period associated with early cabazitaxel taxoid patenting |
| 1998 |
U.S. Patent No. 5,847,170 issued |
| June 17, 2010 |
FDA approved Jevtana |
| June 2015 |
Five-year new chemical entity exclusivity period generally ended |
| 2015 onward |
Later-expiring formulation and use claims became commercially relevant |
| 2021 onward |
FDA-approved generic cabazitaxel injection competition expanded |
| Current period |
Jevtana remains marketed, but with mature-brand erosion |
The exact generic launch date depended on the applicant, litigation resolution, settlement provisions, and market strategy. Generic cabazitaxel is not protected by biologic exclusivity and does not face biosimilar-specific regulatory barriers.
What patents protect cabazitaxel and Jevtana?
The cabazitaxel estate has historically included composition, formulation, dosage, and method-of-use claims. The practical strength of each category differs.
Composition patents
The earliest taxoid patents protected cabazitaxel or related derivatives. U.S. Patent No. 5,847,170 is the principal publicly identifiable early patent associated with this technology. Composition protection is generally the strongest patent category because it can cover the active ingredient across indications and formulations. Its commercial duration, however, ended before the current period.
Formulation patents
Cabazitaxel is supplied as a concentrated solution requiring dilution before infusion. Formulation and excipient claims can address stability, concentration, solvent systems, dilution conditions, and ready-to-use or simplified administration formats.
Formulation patents can delay or complicate generic entry when they are listed in the Orange Book and remain enforceable. Their strength depends on claim scope, design-around options, prosecution history, and whether generic applicants certify against the patents.
Method-of-use patents
Method patents may cover treatment of prostate cancer with cabazitaxel, dosing schedules, patient selection, combination therapy, or treatment after prior docetaxel and androgen-receptor pathway inhibition.
Use patents are commercially weaker than composition patents when physicians can prescribe the generic for unpatented uses. Their practical effect depends on the specificity of the indication, the availability of skinny-label strategies, prescribing behavior, reimbursement controls, and induced-infringement evidence.
Patent-estate assessment
| Patent category |
Historical relevance |
Current commercial strength |
| Composition |
Broad active-ingredient coverage |
Low after expiry |
| Formulation |
May cover injectable stability and presentation |
Moderate where claims remain enforceable |
| Method of use |
May cover sequencing and patient populations |
Moderate to low, depending on label and enforcement |
| Manufacturing |
May protect crystallization, purification, or process controls |
Relevant to supply barriers, less effective against a compliant alternative process |
| Regulatory exclusivity |
Delayed ANDA approval during the exclusivity period |
Expired |
Public patent records should be reconciled with the current FDA Orange Book before making a launch or litigation decision. Patent expiration can vary because of terminal disclaimers, patent-term adjustment, pediatric exclusivity, patent-term extension, and listed-use scope.
What is the Orange Book status of Jevtana?
Jevtana is an FDA-approved small-molecule drug listed under NDA 201023. The Orange Book historically included patents covering the product and related formulations or uses. Because cabazitaxel is a conventional small molecule, generic applicants can file ANDAs and use Paragraph IV certifications against listed patents.
The commercial relevance of an Orange Book patent depends on whether:
- The patent remains listed and unexpired.
- The patent covers the proposed generic product or labeled use.
- The generic applicant filed a Paragraph IV certification.
- The NDA holder filed a patent-infringement action within 45 days.
- A 30-month stay or settlement agreement affected approval timing.
- The generic can launch with a carve-out for patented use claims.
Which companies are challenging Jevtana?
Generic injectable manufacturers have challenged Jevtana through ANDA filings and market entry. Publicly identified participants in the cabazitaxel injection market have included companies such as Teva, Fresenius Kabi, Accord Healthcare, and other generic oncology suppliers, depending on the jurisdiction and product presentation.
The competitive set can change rapidly because FDA approvals, discontinuations, supply contracts, and wholesaler listings are not static. The relevant commercial question is not only which companies have approval, but which suppliers have active inventory, reliable sterile manufacturing, and contracts with hospitals and group purchasing organizations.
What does a Paragraph IV challenge mean for cabazitaxel?
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. If the NDA holder files suit within 45 days, FDA approval may be stayed for up to 30 months, subject to court action and statutory exceptions.
For cabazitaxel, Paragraph IV activity was most important before the principal formulation and use barriers weakened. Once multiple generics received approval or entered through settlement-based timing, the commercial value of further patent challenges decreased. Generic competition then shifted from legal timing to price, supply, and contracting.
What generic entry risks exist for Jevtana?
Generic entry risk is high because cabazitaxel is an approved small-molecule injectable with no remaining new chemical entity exclusivity. The principal barriers are sterile manufacturing, regulatory compliance, product quality, and oncology distribution rather than a broad active-ingredient patent.
Generic launch scenarios
| Scenario |
Market effect |
| One or two approved generics |
Moderate price pressure; Sanofi may retain institutional accounts |
| Three or more active suppliers |
Significant net-price erosion and tender competition |
| Supply disruption at a generic manufacturer |
Temporary recovery in branded or alternative-generic demand |
| Broad hospital substitution |
Rapid branded volume loss |
| Narrow generic distribution |
Slower erosion in specialist centers and smaller markets |
| Successful use-patent enforcement |
Limited impact if generics carve out patented indications |
Injectable oncology products can experience abrupt market changes. A shortage may temporarily improve branded demand, while a new supplier with aggressive pricing can reduce revenue quickly. Manufacturing scale and sterility assurance are material competitive factors.
Is there biosimilar risk for cabazitaxel?
No. Cabazitaxel is a chemically synthesized small molecule, not a biologic. Its direct competitive threat is generic cabazitaxel under the ANDA pathway, not a biosimilar under the Public Health Service Act.
Biosimilar competition affects other prostate cancer and oncology products, including biologic supportive-care agents, but it does not change the regulatory pathway for cabazitaxel. The more relevant substitution risk comes from oral hormonal therapies, radioligand therapy, PARP inhibitors, and other treatments that alter the sequencing of metastatic castration-resistant prostate cancer.
What litigation and settlements affect cabazitaxel?
Cabazitaxel’s litigation history has centered on ANDA challenges to patents listed for Jevtana and related formulations or methods. Generic applicants typically seek to invalidate listed patents or establish noninfringement. Settlements can establish licensed or agreed launch dates before the final expiration of a patent.
The financial effect of a settlement depends on:
- The first generic launch date.
- Whether the settlement permits multiple generic entrants.
- Any authorized-generic arrangement.
- Restrictions on dosage strengths or formulations.
- The extent of patent claims carved out of the generic label.
- The presence of co-defendants and shared launch rights.
The current commercial risk is broad generic erosion rather than a single pending challenge. The loss of exclusivity has already changed the market from a branded monopoly to multi-supplier procurement.
Does Sanofi have a licensing or partnership strategy for cabazitaxel?
Cabazitaxel originated from the taxane research and commercial portfolio associated with Sanofi and its predecessor organizations. Jevtana has primarily been commercialized as a Sanofi product rather than through a high-profile late-stage licensing transaction.
The strategic value of the product is tied to Sanofi’s established oncology infrastructure, regulatory approvals, manufacturing network, and hospital relationships. A meaningful future licensing opportunity would more likely involve regional commercialization, generic supply, authorized-generic rights, or manufacturing arrangements than a conventional innovative-drug co-development deal.
How strong is the cabazitaxel patent estate?
The estate is commercially weak against broad generic entry because the earliest active-ingredient protection has expired and regulatory exclusivity ended years ago. Remaining formulation, method, or process claims may still create targeted enforcement opportunities, but they are unlikely to restore monopoly economics.
Strength rating
| Dimension |
Assessment |
| Active ingredient protection |
Expired or commercially exhausted |
| Formulation protection |
Potentially relevant but design-around risk is high |
| Method-of-use protection |
Limited by label carve-outs and prescribing practices |
| Manufacturing barriers |
Meaningful for sterile injectables |
| Regulatory exclusivity |
Expired |
| Litigation leverage |
Reduced after generic approvals and settlements |
| Commercial durability |
Low to moderate in selected markets |
| Generic launch risk |
High |
What is the likely financial trajectory for cabazitaxel?
The base case is continued revenue contraction, with periodic volatility from supply disruptions, pricing changes, and country-specific generic penetration. Sanofi may preserve a residual branded business in markets where physicians or hospitals value established supply and where generic uptake is incomplete.
The principal downside factors are:
- Additional generic suppliers.
- Lower hospital acquisition prices.
- Reduced treatment duration in heavily pretreated patients.
- Earlier use of radioligand therapy and targeted agents.
- Greater use of oral androgen-receptor inhibitors before chemotherapy.
- Reimbursement pressure in Europe and other regulated markets.
Potential stabilizing factors include persistent clinical use after docetaxel and androgen-receptor pathway inhibitors, guideline support from comparative evidence, and manufacturing barriers that reduce the number of reliable injectable suppliers.
Cabazitaxel is unlikely to return to its historical growth profile without a major new indication, a substantially differentiated formulation, or a commercial structure that captures generic supply economics. The most probable outcome is a declining specialty-oncology franchise with residual cash flow and limited strategic upside.
Key Takeaways
- Cabazitaxel is a late-line intravenous taxane for metastatic castration-resistant prostate cancer after docetaxel.
- Jevtana sales have declined from approximately €370 million in 2019 as generic competition expanded.
- U.S. new chemical entity exclusivity ended in 2015, and the core composition patent no longer protects the current market.
- Formulation and method-of-use patents may have delayed or shaped generic entry, but they do not provide broad current exclusivity.
- Generic cabazitaxel creates high price and volume risk, particularly in U.S. hospital channels.
- Cabazitaxel has generic risk, not biosimilar risk.
- Sterile injectable manufacturing and supply reliability are now more important than the expired composition patent.
- The base-case financial outlook is continued decline with residual branded revenue in selected markets.
FAQs
What is the expected generic price impact on Jevtana?
Generic entry generally produces substantial reductions in acquisition price, particularly after several suppliers enter. The impact on Sanofi depends on hospital substitution, contracting, and the number of active manufacturers.
Can a generic cabazitaxel product launch with a narrower label?
Yes. An ANDA applicant may use a labeling carve-out for a patented method of use if the remaining label supports approval and does not create prohibited promotional conduct.
Is cabazitaxel included in Medicare oncology reimbursement?
Medicare reimbursement depends on the treatment setting, billing pathway, physician office or hospital outpatient status, and applicable payment rules. Drug acquisition economics and reimbursement spreads influence whether providers prefer branded or generic supply.
Could a new cabazitaxel formulation extend market exclusivity?
A new formulation could receive patent protection and, if clinically meaningful, regulatory benefits. It would need to demonstrate commercial differentiation because an ordinary reformulation may face limited substitution resistance.
Does cabazitaxel compete directly with Pluvicto?
It can compete for later-line metastatic castration-resistant prostate cancer patients, but the therapies have different eligibility requirements. Pluvicto requires PSMA-positive disease and radioligand-therapy infrastructure, while cabazitaxel is an established chemotherapy option after prior treatment.
References
-
de Wit, R., de Bono, J., Sternberg, C. N., Fizazi, K., Tombal, B., Wülfing, C., Kramer, G., Eymard, J.-C., Bamias, A., Carles, J., Iacovelli, R., Crosetto, N., Davis, N. B., Zafeiridis, A., Ladoire, S., & CARD Investigators. (2019). Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. New England Journal of Medicine, 381(26), 2506-2518.
-
Sanofi. (2020). 2020 annual report. Sanofi.
-
Sanofi. (2021). 2021 annual report. Sanofi.
-
Sanofi. (2022). 2022 annual report. Sanofi.
-
Sanofi. (2023). 2023 annual report. Sanofi.
-
Sanofi. (2024). 2024 annual report. Sanofi.
-
U.S. Food and Drug Administration. (2023). Jevtana (cabazitaxel) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Patent No. 5,847,170. (1998). Taxoid derivatives. United States Patent and Trademark Office.
